News

Twenty more travel grants available for RSV Vaccines for the World, Málaga

Posted on August 09, 2017

We highly encourage junior or mid-stage career researchers and scientists/physicians from low and middle income countries to attend RSVVW. If you want be considered for a travel grant, please send an email with your details (country, current position, university) and abstract to info@resvinet.org to subscribe. Selection will be based on the quality of abstracts and geographic location of the author. Online registration is not needed. Please note that the deadline is September 1, 2017. Visit our website for more information.

read more

Julius Clinical Awarded Two EU Grants for Clinical Studies

Posted on August 02, 2017

Zeist, 01 August 2017. Julius Clinical today announced that the European Commission granted the consortiums working on both the HIT-Cystic Fibrosis and Convince projects with financial funding to conduct these highly important clinical studies. Julius Clinical is a proud partner in these projects and will provide the operational services.   

HIT-CF
In the HIT-CF project, the aim is to bring personalised disease-modifying therapies to cystic fibrosis (CF) patients with ultra-rare CFTR mutation. These patients could otherwise never get access to such treatment. Once the unique concepts has been proven, the CF community can extend the  state-of-the-art methodology to all CF patients such that HIT-CF will impact the entire CF field.

H2020 CONVINCE
This consortium aims to determine the best possible dialysis treatment by comparing the conventional guideline based haemodialysis treatment versus high-dose haemodiafiltration. This will be done by carrying out a prospective randomized controlled clinical trial. The study will deliver an answer to the question about which intervention gives the best value for money. As such, it will be considered a landmark study, and the consortium will be allowed  to publish an “end of discussion” paper.

read more

RSV Vaccines for the World Conference: Travel Grants Available

Posted on August 01, 2017

We are happy to inform you that we have travel grants for junior or mid-stage career researchers. EU awardees will receive 1000 Euro, non-EU awardees will receive 2000 Euro as a lump sum for all expenses. At least 20 travel grants will be available. Applicants are required to submit an abstract. If there are more applicants than available grants as of August 7, selection will be based on the quality of abstracts and geographic location of the author. After August 7, additional travel grants may be awarded based on availability of funds as well as abstract quality.

We highly encourage young researchers (specifically from low and middle income countries) to be part of RSV Vaccines for the World in November. If you want be considered for a travel grant, please send an email with your details (country, current title, university) and abstract to info@resvinet.org to subscribe. Online registration is not needed.  

read more

RSV Vaccines for the World Conference - registration open

Posted on July 25, 2017

We are delighted to announce that online registration is open for the RSV Vaccines For The World conference 2017.

The goal of the conference is to bring together the scientific data and expertise (mainly focusing on vaccine developments) and connecting the stakeholders involved in RSV research. Researchers and physicians from all over the world are invited to join the discussions and share their knowledge. Specifically, scientists and physicians from low- and middle income countries (LMICs) and young researchers are being encouraged and supported to participate in this meeting. This year, the conference will be held on 29 November-01 December in Malaga, Spain.

read more

Real world evidence in medicine development - sign up now

Posted on July 21, 2017

IMI’s GetReal project (www.imi-getreal.eu) will run the first edition of an interactive online course entitled ‘Real-world evidence in medicine development’ from 2 October to 12 November 2017. Under the supervision of leading academics from the project, the course will provide participants with an introduction to the topics covered by GetReal, and present the current techniques, opportunities and challenges for the use of real-world evidence in medicine development.

read more

Andrew Copestake joins Julius Clinical

Posted on May 05, 2017

Julius Clinical is proud to announce that Andrew Copestake has been appointed as our new Chief Business Development Officer starting immediately. He will be part of the Management team together with Messrs. Smink (CEO), Grobbee (CSO) and Van Dijk (COO).

read more

Julius Clinical Forms Alliance With Parexel

Posted on April 04, 2017

Alliance aims to strengthen global clinical trial services by aligning scientific and operational aspects of clinical trials

Utrecht, Netherlands, January 25, 2017 — Julius Clinical, a globally-operating Academic Research Organization (ARO), today announced it has entered into a non-exclusive alliance with PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation. The alliance provides biopharmaceutical companies an approach to aligning scientific and operational aspects of a clinical trial.

Through this alliance, Julius Clinical and PAREXEL offer biopharmaceutical companies a unified approach for studies by providing scientific leadership, peer-to-peer networks, operational excellence and global governance. Sponsor companies can reduce the challenge of managing multiple service providers on a single study by providing seamless access to the strengths of both organisations.  

“Julius Clinical’s scientific leaders have broad experience on study committees and are able to work effectively with international networks of thought leaders and high-recruiting sites. Combining Julius Clinical’s expertise and team with PAREXEL’s global operational capabilities, will result in efficiently designed and operated trials with high scientific standards and faster recruitment, accelerating development of products,” said Aize Smink, CEO, Julius Clinical.

“PAREXEL recognises that of paramount importance to our clients is access to a broad pool of highly engaged site networks and external academic leadership and capabilities to help deliver medicines that meet patients’ needs,” said Paul Evans, Ph.D., Corporate Vice President, Global Site Solutions, PAREXEL. “This alliance will provide our clients access to the complimentary expertise of both organizations in a streamlined manner, reducing the burden of managing multiple parties and thus the associated costs.”

read more